| Search by tag or site | Login to my blog ? Start my own blog |
![]() |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Tycoon To Acquire 25% Stake In Sanguibiotech
Posted on 04/13/2007 10:09:48 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Tycoon Venture Capital & Investment of London said today that it would acquire 25% of SanguiBioTech GmbH, a German subsidiary of Sangui BioTech International that makes pharmaceuticals and devices focused on biological regeneration of cells through compensatory supply of vital substrates. As part of the agreement with Tycoon, the venture firm is offering Sangui a mezzanine loan of roughly $10 million. A managing director for the firm said, “We have thoroughly examined the properties and market potential of Sangui’s existing product portfolio, as well as the possible future blockbuster qualities of its haemoglobin polymer blood additive, and we are excited to have the opportunity to participate in the highly promising prospects of this company.”
In addition to the blood additive, SanguiBioTech is hard at work on its GlucoTector product, a long-term implantable glucose sensor for the continuous measurement of glucose levels; the device enables continuous control over three to five years. The sensors are based on optical measuring methods. These methods allow for bloodless and pain-free instant measurement with the advantage of a 24-hour control. The sensors provide data that can be used to analyze patients’ blood glucose levels for a defined period.
SanguiBioTech says the GlucoTector is an improvement over current monitors for the following reasons:
A more pressing concern among some diabetes sufferers, though, might be: How will it look?
Source: OneMedPlace.com
_____________________
Med Tech Sentinel
Tycoon Venture Capital & Investment of London said today that it would acquire 25% of SanguiBioTech GmbH, a German subsidiary of Sangui BioTech International that makes pharmaceuticals and devices focused on biological regeneration of cells through compensatory supply of vital substrates. As part of the agreement with Tycoon, the venture firm is offering Sangui a mezzanine loan of roughly $10 million. A managing director for the firm said, “We have thoroughly examined the properties and market potential of Sangui’s existing product portfolio, as well as the possible future blockbuster qualities of its haemoglobin polymer blood additive, and we are excited to have the opportunity to participate in the highly promising prospects of this company.”
In addition to the blood additive, SanguiBioTech is hard at work on its GlucoTector product, a long-term implantable glucose sensor for the continuous measurement of glucose levels; the device enables continuous control over three to five years. The sensors are based on optical measuring methods. These methods allow for bloodless and pain-free instant measurement with the advantage of a 24-hour control. The sensors provide data that can be used to analyze patients’ blood glucose levels for a defined period.
SanguiBioTech says the GlucoTector is an improvement over current monitors for the following reasons:
1. It uses at least two independent optical measurement systems in one sensor, which guarantees a high signal reliability and increased sensitivity
2. Measurements of glucose levels are also possible in quantities of less than 40 mg/dL which is significant for the assessment of brain damage
3. Glucose concentration results can be measured from a clearly defined, physically simple system (cuvet measurement).
A more pressing concern among some diabetes sufferers, though, might be: How will it look?
Source: OneMedPlace.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
![]()
Examples
ATM Wallstreet - Tue Jul 08, 2008 02:28PM
Why I traded the stock ME today. I had it on my list fr [read more]
Why I traded the stock ME today. I had it on my list fr [read more]
Morpheus Trading - Thu Jul 03, 2008 07:49AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Sun Jul 06, 2008 11:00PM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]












<< My Home | TheMoneyBlogs Home